Lumigan

Common use

Keep in mind that the use of Lumigan eye drops does not represent a cure for glaucoma. It is a treatment prescribed by doctors in patients with glaucoma, which reduces the risk of optic nerve damage and in consequence blindness. A structure in our eyes constantly secrete a liquid which has the function of providing the nutrients which are needed. In order for the eye to function properly, a balance must be kept between the secretion and the excretion function. When the excretion function is very slow, the liquid above mentioned will start to build up inside the eye, thus causing a spike in the intra ocular pressure. If this balance is not corrected, the high intra ocular pressure will lead to damage to the optic nerve, and in time to blindness. Lumigan eye drops facilitate the excretion of the liquid, maintaining a stable balance between secretion and excretion.

Dosage and direction

The accepted dose for Lumigan eyedrop solution is one drop of 0.01% solution in the eye affected by glaucoma. If both are are affected, than one drop should be administered in each eye.
To apply the drops, first remove your contact lenses as they may absorb a part of the active ingredients which are contained by Lumigan eyedrops. After applying the eye drops directly into the eye, gently close and open the eye in order to spread the solution all across the surface. Do not use your hands to rub your eyes, as this may result in doing more damage than good.

Precautions

Always make sure that your hands, as well as the bottle are clean before applying the solution. This is to prevent opening a gateway for oportunistic infections.
Please not that Lumigan eyedrops may cause temporary blurry vision, so abstain from driving or operating heavy machinery until the effect has worn off and you are able once again to perform your daily activities.

Contraindications

Because the effects of this drug have not been studied on patients with liver or renal disease, consult your physician before administering the drops if you are known to have one or both types of the above mentioned diseases.
If you are allergic or have hipersensitivity to any of the active ingredients of the Lumigan Eyedrops, do not administer the drug. Consult the list of active ingredients before applying Lumigan Eyedrops.
Also, tell your doctor if you are suffering or have recently suffered from any eye infections.

Possible side effect

Possible side effects of using this drug may include redness of the eye, eyes changing colour, itching, swelling, dizziness. If you are experiencing any of these symptoms on a daily basis, seek physician care immediately.

Drug interaction

After studying the drug, it has been found that Lumigan Eye drops can interact with bimatoprost topical (Latisse), and latanoprost ophtalmic (Xalatan)


Missed dose

If by any chance you happen to miss your daily dose of Lumigan eyedrops, take it as soon as you remember, as long as it is not already the time for your next dose. Do not double dose.

Overdose

If you are under the impression of having overdosed, seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Storage

Lumigan eyedrops should be kept stored in a place where direct sunlight does not shine, at a preferred temperature of unde 25 degrees Celsius, away from moisture and especially away from children.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.

Clinical Verification

Last Clinically Updated: August 15, 2026

Written By

Dr. Elena Vance, PharmD

Clinical Specialist in Neuropharmacology

Fact Checked By

Marcus Thorne, MS

Biomedical Data & FDA Label Verification

Medically Reviewed By

Dr. Arthur Campbell, MD

Board-Certified Psychiatrist (ABPN)